Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury

FHHep518

Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19

2020-06-01

2021-12-31

2021-12-31

Terminated

Early phase I

13

Inclusion Criteria: * Age ≥18 years * Admitted to the intensive care unit * Positive COVID-19 PCR * Mechanical Ventilation for ≤ 48 hours * PaO2/FiO2 ≤300 Exclusion Criteria: * Heparin allergy * Active bleeding * Death or withdraw of care anticipated by intensivist within 24 hours * Platelets\< 50,000 cells/µL * Clinically significant coagulopathy, as decided by the intensivist * O2 dependent at baseline

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 13, 'type': 'ACTUAL'}}

2024-04-03